1. Heath K, Levi J, Hill A. The Joint United Nations Programme on HIV/AIDS 95-95-95 targets: worldwide clinical and cost benefits of generic manufacture. AIDS [Internet]. 2021 Dec 15 [cited 2022 Jun 15];35(Supplement 2):S197. Available from: https://journals.lww.com/aidsonline/Fulltext/2021/12152/The_Joint_United_Nations_Programme_on_HIV_AIDS.12.aspx.
2. Jewell BL, Mudimu E, Stover J, Brink D, ten, Phillips AN, Smith JA, et al. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. The Lancet HIV [Internet]. 2020 Sep 1 [cited 2022 Aug 29];7(9):e629–40. Available from: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30211-3/fulltext.
3. Zhang G, DeVos J, Medina-Moreno S, Wagar N, Diallo K, Beard RS, et al. Utilization of Dried Blood Spot Specimens Can Expedite Nationwide Surveillance of Hiv Drug Resistance in Resource-Limited Settings. PLoS One [Internet]. 2018 Sep 7 [cited 2022 Aug 26];13(9):e0203296. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128523/.
4. Johannessen A. Dried blood spots in HIV monitoring: applications in resource-limited settings. Bioanalysis [Internet]. 2010 Nov [cited 2022 Aug 27];2(11):1893–908. Available from: https://www.future-science.com/doi/full/10.4155/bio.10.120.
5. Organization WH. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization; 2016.